XTX Topco Ltd Invests $215,000 in PROCEPT BioRobotics Co. (NASDAQ:PRCT)

XTX Topco Ltd bought a new stake in PROCEPT BioRobotics Co. (NASDAQ:PRCT) during the 2nd quarter, HoldingsChannel reports. The firm bought 3,521 shares of the company’s stock, valued at approximately $215,000.

A number of other institutional investors have also bought and sold shares of the company. Mark Sheptoff Financial Planning LLC bought a new position in shares of PROCEPT BioRobotics in the 2nd quarter worth about $36,000. Quest Partners LLC lifted its stake in PROCEPT BioRobotics by 2,492.3% in the second quarter. Quest Partners LLC now owns 674 shares of the company’s stock valued at $41,000 after buying an additional 648 shares during the period. Fairman Group LLC acquired a new position in PROCEPT BioRobotics in the fourth quarter valued at approximately $84,000. RiverPark Advisors LLC bought a new position in shares of PROCEPT BioRobotics during the 2nd quarter worth approximately $135,000. Finally, nVerses Capital LLC grew its position in shares of PROCEPT BioRobotics by 300.0% during the 2nd quarter. nVerses Capital LLC now owns 2,400 shares of the company’s stock worth $147,000 after buying an additional 1,800 shares during the period. Institutional investors own 89.46% of the company’s stock.

PROCEPT BioRobotics Price Performance

Shares of NASDAQ PRCT opened at $79.53 on Monday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 6.49 and a current ratio of 7.51. The firm’s 50-day simple moving average is $72.35 and its 200 day simple moving average is $63.84. The stock has a market cap of $4.09 billion, a price-to-earnings ratio of -37.51 and a beta of 1.03. PROCEPT BioRobotics Co. has a fifty-two week low of $24.83 and a fifty-two week high of $85.81.

PROCEPT BioRobotics (NASDAQ:PRCT) last announced its earnings results on Thursday, August 1st. The company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.02. PROCEPT BioRobotics had a negative return on equity of 37.85% and a negative net margin of 58.73%. The company had revenue of $53.35 million for the quarter, compared to analysts’ expectations of $50.10 million. During the same quarter in the previous year, the firm earned ($0.56) earnings per share. PROCEPT BioRobotics’s quarterly revenue was up 61.2% on a year-over-year basis. As a group, research analysts anticipate that PROCEPT BioRobotics Co. will post -1.88 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on PRCT shares. TD Cowen boosted their target price on shares of PROCEPT BioRobotics from $75.00 to $99.00 and gave the company a “buy” rating in a research report on Monday, September 16th. Bank of America increased their price objective on shares of PROCEPT BioRobotics from $80.00 to $94.00 and gave the stock a “buy” rating in a research report on Thursday, August 22nd. Wells Fargo & Company boosted their target price on PROCEPT BioRobotics from $67.00 to $69.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. Finally, Truist Financial increased their price target on PROCEPT BioRobotics from $74.00 to $95.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, PROCEPT BioRobotics presently has an average rating of “Buy” and an average target price of $78.17.

Insider Activity

In related news, Director Antal Rohit Desai sold 35,220 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $76.12, for a total transaction of $2,680,946.40. Following the transaction, the director now directly owns 23,963 shares in the company, valued at $1,824,063.56. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other PROCEPT BioRobotics news, Director Antal Rohit Desai sold 35,220 shares of PROCEPT BioRobotics stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $76.12, for a total transaction of $2,680,946.40. Following the transaction, the director now owns 23,963 shares of the company’s stock, valued at approximately $1,824,063.56. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Kevin Waters sold 25,000 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $82.51, for a total value of $2,062,750.00. Following the completion of the transaction, the chief financial officer now directly owns 96,096 shares of the company’s stock, valued at $7,928,880.96. The disclosure for this sale can be found here. Insiders sold a total of 154,892 shares of company stock worth $12,134,665 over the last quarter. Insiders own 17.40% of the company’s stock.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).